Dysregulations and mutations, such as lack of deubiquitinating activity (C91A substitution) or second nuclear localization signal within the BAP1 gene, have been identified as drivers in many human cancers, such as uveal melanoma,15 mesothelioma,16 clear cell renal cell carcinoma,17 leukemia,18 and breast cancer.19 This evidence concerns the gene BAP1 and breast cancer.